Comprehensive medicinal chemistry II: 3 Drug discovery technologies
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Amsterdam [u.a.]
Elsevier
2007
|
| Ausgabe: | 1. ed. |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXIX, 1037 S. Ill., graph. Darst. |
| ISBN: | 0080445160 9780080445168 |
Internformat
MARC
| LEADER | 00000nam a2200000 cc4500 | ||
|---|---|---|---|
| 001 | BV022238844 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 070124s2007 ad|| |||| 00||| eng d | ||
| 020 | |a 0080445160 |9 0-08-044516-0 | ||
| 020 | |a 9780080445168 |9 978-0-08-044516-8 | ||
| 035 | |a (OCoLC)634912343 | ||
| 035 | |a (DE-599)BVBBV022238844 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-20 | ||
| 245 | 1 | 0 | |a Comprehensive medicinal chemistry II |n 3 |p Drug discovery technologies |c ed.-in-chief: John B. Taylor... |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a Amsterdam [u.a.] |b Elsevier |c 2007 | |
| 300 | |a XXIX, 1037 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 700 | 1 | |a Taylor, John B. |e Sonstige |4 oth | |
| 773 | 0 | 8 | |w (DE-604)BV022238800 |g 3 |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015449802&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015449802 | ||
Datensatz im Suchindex
| _version_ | 1804136229726322688 |
|---|---|
| adam_text | COMPREHENSIVE MEDICINAL CHEMISTRY II EDITORS-IN-CHIEF DR JOHN B TAYLOR
FORMER SENIOR VICE-PRESIDENT FOR DRUG DISCOVERY, RHONE-POULENC RORER,
WORLDWIDE, UK PROFESSOR DAVID J TRIGGLE STATE UNIVERSITY OF NEW YORK,
BUFFALO, NY, USA VOLUME 3 DRUG DISCOVERY TECHNOLOGIES VOLUME EDITOR
PROFESSOR HUGO KUBINYI UNIVERSITY OF HEIDELBERG, HEIDELBERG, GERMANY
ELSEVIER AMSTERDAM BOSTON HEIDELBERG LONDON NEW YORK OXFORD PARIS SAN
DIEGO SAN FRANCISCO SINGAPORE SYDNEY TOKYO CONTENTS CONTENTS OF ALL
VOLUMES XI PREFACE X J X PREFACE TO VOLUME 3 XXI EDITORS-IN-CHIEF XXIII
EDITOR OF VOLUME 3 XXIV CONTRIBUTORS TO VOLUME 3 XXV TARGET SEARCH 3.01
GCNOMICS 1 J S CALDWELL, S K CHANDA, J IRELAN, AND R KOENIG, GCNOMICS
INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION, SAN DIEGO, CA, USA 3.02
PROTEOMICS 27 H VOSHOL, S HOVING, AND J VAN OOSTRUM, NOVARTIS INSTITUTES
FOR BIOMCDICAL RESEARCH, GENOME AND PROTCOMC SCIENCES, BASEL,
SWITZERLAND 3.03 PHARMACOGENOMICS 51 K LINDPAINTNER, F. HOFFMAN-LA
ROCHE, BASEL. SWITZERLAND 3.04 BIOMARKERS 69 S E DEPRIMO, PFIZER GLOBAL
RESEARCH AND DEVELOPMENT, SAN DIEGO, CA, USA 3.05 MICROARRAYS 87 D
AMARATUNGA, JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT LLC,
RARITAN, NJ, USA, AND H GOHLMANN AND P J PEETERS. JOHNSON C6 JOHNSON
PHARMACEUTICAL RESEARCH & DEVELOPMENT, BEERSC. BELGIUM 3.06 RECOMBINANT
DEOXYRIBONUCLEIC ACID AND PROTEIN EXPRESSION 107 F BERNHARD, C KLAMMT.
AND H RUTERJANS. UNIVERSITY OF FRANKFURT I MAIN, GERMANY 3.07 CHEMICAL
BIOLOGY 129 R FLAUMENHAFT, HARVARD MEDICAL SCHOOL, BOSTON, MA, USA VIII
CONTENTS TARGET VALIDATION 3.08 GENETICALLY ENGINEERED ANIMALS 151 B
BOLON, GEMPATH INC., CEDAR CITY, UF. USA 3.09 SMALL INTERFERING
RIBONUCLEIC ACIDS 171 L GIANELLINI AND J MOLL, NERVIANO MEDICAL SCIENCES
S.R.L, NERVIANO, ITALY 3.10 SIGNALING CHAINS 189 M-H TEITEN, R BLASIUS,
F MORCEAU, AND M DIEDERICH, HOPITAL KIRCHBERG, LUXEMBOURG CITY,
LUXEMBOURG, AND M DICATO, CENTRE HOSPITALIER DE LUXEMBOURG, LUXEMBOURG
CITV, LUXEMBOURG 3.11 ORTHOGONAL LIGAND-RECEPTOR PAIRS 215 F C ACHER,
UNIVERSITE RENE DESCARTES PARIS V, PARIS, FRANCE INFORMATICS AND
DATABASES 3.12 CHEMOINFORMATICS 235 V J GILLET, UNIVERSITY OF SHEFFIELD,
SHEFFIELD, T/K AND A R LEACH, GLAXOSMITHKLINE, STEVENAGE, UK 3.13
CHEMICAL INFORMATION SYSTEMS AND DATABASES 265 T ENGEL, CHEMICAL
COMPUTING GROUP AG, KOLN, GERMANY AND E ZASS, INFORMATIONSZENTRUM CHEMIE
BIOLOGIC PHARMAZIE, ZURICH, SWITZERLAND 3.14 BIOACTIVITY DATABASES 293 M
OLAH AND T I OPREA, UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE,
ALBUQUERQUE, NM, USA 3.15 BIOINFORMATICS 315 T LENGAUER AND C HARTMANN,
MAX PLANCK INSTITUTE FOR INFORMATICS, SAARHRUCKEN, GERMANY 3.16 GENE AND
PROTEIN SEQUENCE DATABASES 349 M-J MARTIN, T KULIKOVA, M PRUESS, AND R
APWEILER, EMBL OUTSTATION EUROPEAN BIOINFORMATICS INSTITUTE, HINXTON,
CAMBRIDGE, UK 3.17 THE RESEARCH COLLABORATOR FOR STRUCTURAL
BIOINFORMATICS PROTEIN DATA BANK 373 P E BOURNE, W F BLUHM, N DESHPANDE,
AND Q ZHANG, UNIVERSITY OF CALIFORNIA, LA JOLLA, CA, USA, AND H M BERMAN
AND J L FLIPPEN-ANDERSON, RUTGERS - THE STATE UNIVERSITY OF NEW JERSEY,
PISCATAWAY, NJ, USA 3.18 THE CAMBRIDGE CRYSTALLOGRAPHIC DATABASE 389 F H
ALLEN, G M BATTLE, AND S ROBERTSON, CAMBRIDGE CRYSTALLOGRAPHIC DATA
CENTRE, CAMBRIDGE, UK STRUCTURAL BIOLOGY 3.19 PROTEIN PRODUCTION FOR
THREE-DIMENSIONAL STRUCTURAL ANALYSIS 411 M M T BAUER AND G SCHNAPP,
BOEHRINGER INGELHEIM PHARMA, BIHERACH, GERMANY 3.20 PROTEIN
CRYSTALLIZATION 433 G E SCHULZ, ALBERT-LUDWIGS-U NIVERSITAT, FREIBURG IM
BREISGAU, GERMANY 3.21 PROTEIN CRYSTALLOGRAPHY 449 M T STUBBS II, MARTIN
LUTHER UNIVERSITY, HALLE, GERMANV CONTENTS IX 3.22 BIO-NUCLEAR MAGNETIC
RESONANCE 473 T CARLOMAGNO, M BALDUS, AND C GRIESINGER. MAX PLANCK
INSTITUTE FOR BIOPHYSICAL CHEMISTRY. GOTTINGEN. GERMANY 3.23 PROTEIN
THREE-DIMENSIONAL STRUCTURE VALIDATION 507 R P JOOSTEN, CENTRE FOR
MOLECULAR AND BIOMOLECULAR INFORMATICS, NIJMEGEN. THE NETHERLANDS, AND G
CHINEA, CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY. HAVANA, CUBA,
AND G J KLEYWEGT. UNIVERSITY OF UPPSALA, UPPSALA. SWEDEN, AND G VRIEND,
CENTRE FOR MOLECULAR AND BIOMOLECULAR INFORMATICS, NIJMEGEN, THE
NETHERLANDS 3.24 PROBLEMS OF PROTEIN THREE-DIMENSIONAL STRUCTURES 531 R
A LASKOWSKI AND G J SWAMINATHAN. EUROPEAN BIOINFORMATICS INSTITUTE.
WELLCOME TRUST GENOME CAMPUS, HINXTON, CAMBRIDGE, UK 3.25 STRUCTURAL
GENOMICS 551 W SHI AND M R CHANCE, CASE WESTERN RESERVE UNIVERSITY.
CLEVELAND. OH. USA SCREENING 3.26 COMPOUND STORAGE AND MANAGEMENT 561 W
W KEIGHLEY. T P WOOD, AND T J WINCHESTER. PFIZER GLOBAL RESEARCH AND
DEVELOPMENT. SANDWICH. UK 3.27 OPTICAL ASSAYS IN DRUG DISCOVERY 577 B
SCHNURR. T AHRENS, AND U REGENASS. DISCOVERY PARTNERS INTERNATIONAL AG,
ALLSCHWIL, SWITZERLAND 3.28 FLUORESCENCE SCREENING ASSAYS 599 D ULLMANN,
EVOTEC AG, HAMBURG. GERMANY 3.29 CELL-BASED SCREENING ASSAYS 617 A
WEISSMAN, J K.EEFER. A MIAGKOV. M SATHYAMOORTHY. S PERSCHKE. AND F L
WANG. NOVASCRCEN BIOSCIENCES CORPORATION. HANOVER. MD. USA 3.30 SMALL
ANIMAL TEST SYSTEMS FOR SCREENING 647 M MUDA, S MCKENNA. AND B G HEALEY.
SERONO RESEARCH INSTITUTE. ROCKHNUL. MA. USA 3.31 IMAGING 659 P M
SMITH-JONES. MEMORIAL SLOAN KCLTERING CANCER CENTER. NEW YORK. NY. USA
3.32 HIGH-THROUGHPUT AND HIGH-CONTENT SCREENING 679 M CIK. JOHNSON &
JOHNSON PHARMACEUTICAL RESEARCH CV DEVELOPMENT. BEERSC. BELGIUM AND M R
JURZAK. MERCK KGAA. DARMSTADT. GERMAIN CHEMICAL TECHNOLOGIES 3.33
COMBINATORIAL CHEMISTRY 69 P SEN LCI. DESENZANO DEL GARDA. ITALY 3.34
SOLUTION PHASE PARALLEL CHEMISTRY 7DL M ASHTON AND B MOLONEY. EVOTEC UK
LTD. AHINGDON. IK 3.35 POLYMER-SUPPORTED REAGENTS AND SCAVENGERS IN
SYNTHESIS 791 S V LEY. I R BAXENDALE. AND R M MYERS. UNIVERSITY OF
CAMBRIDGE. CAMBRIDGE. UK CONTENTS 3.36 MICROWAVE-ASSISTED CHEMISTRY 837
C O KAPPE, KARL-FRANZENS-UNIVERSITY GRAZ, GRAZ, AUSTRIA 3.37
HIGH-THROUGHPUT PURIFICATION 861 D B KASSEL, TAKEDA SAN DIEGO. INC., SAN
DIEGO, CA, USA LEAD SEARCH AND OPTIMIZATION 3.38 PROTEIN CRYSTALLOGRAPHY
IN DRUG DISCOVERY 875 T HOGG AND R HILGENFELD, UNIVERSITY OF LIIBECK,
LIIBECK, GERMANY 3.39 NUCLEAR MAGNETIC RESONANCE IN DRUG DISCOVERY 901 J
KLAGES AND H KESSLER, TU MUNCHEN, GARCHING, GERMANY 3.40 CHEMOGENOMICS
921 H KUBINYI, UNIVERSITY OF HEIDELBERG, HEIDELBERG, GERMANY 3.41
FRAGMENT-BASED APPROACHES 939 W JAHNKE, NOVARTIS PHARMA AG, BASEL,
SWITZERLAND 3.42 DYNAMIC LIGAND ASSEMBLY 959 O RAMSTROM, ROYAL INSTITUTE
OF TECHNOLOGY, STOCKHOLM, SWEDEN AND J-M LEHN, ISIS UNIVERSITE LOUIS
PASTEUR, STRASBOURG, FRANCE SUBJECT INDEX 977
|
| adam_txt |
COMPREHENSIVE MEDICINAL CHEMISTRY II EDITORS-IN-CHIEF DR JOHN B TAYLOR
FORMER SENIOR VICE-PRESIDENT FOR DRUG DISCOVERY, RHONE-POULENC RORER,
WORLDWIDE, UK PROFESSOR DAVID J TRIGGLE STATE UNIVERSITY OF NEW YORK,
BUFFALO, NY, USA VOLUME 3 DRUG DISCOVERY TECHNOLOGIES VOLUME EDITOR
PROFESSOR HUGO KUBINYI UNIVERSITY OF HEIDELBERG, HEIDELBERG, GERMANY
ELSEVIER AMSTERDAM BOSTON HEIDELBERG LONDON NEW YORK OXFORD PARIS SAN
DIEGO SAN FRANCISCO SINGAPORE SYDNEY TOKYO CONTENTS CONTENTS OF ALL
VOLUMES XI PREFACE X J X PREFACE TO VOLUME 3 XXI EDITORS-IN-CHIEF XXIII
EDITOR OF VOLUME 3 XXIV CONTRIBUTORS TO VOLUME 3 XXV TARGET SEARCH 3.01
GCNOMICS 1 J S CALDWELL, S K CHANDA, J IRELAN, AND R KOENIG, GCNOMICS
INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION, SAN DIEGO, CA, USA 3.02
PROTEOMICS 27 H VOSHOL, S HOVING, AND J VAN OOSTRUM, NOVARTIS INSTITUTES
FOR BIOMCDICAL RESEARCH, GENOME AND PROTCOMC SCIENCES, BASEL,
SWITZERLAND 3.03 PHARMACOGENOMICS 51 K LINDPAINTNER, F. HOFFMAN-LA
ROCHE, BASEL. SWITZERLAND 3.04 BIOMARKERS 69 S E DEPRIMO, PFIZER GLOBAL
RESEARCH AND DEVELOPMENT, SAN DIEGO, CA, USA 3.05 MICROARRAYS 87 D
AMARATUNGA, JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT LLC,
RARITAN, NJ, USA, AND H GOHLMANN AND P J PEETERS. JOHNSON C6 JOHNSON
PHARMACEUTICAL RESEARCH & DEVELOPMENT, BEERSC. BELGIUM 3.06 RECOMBINANT
DEOXYRIBONUCLEIC ACID AND PROTEIN EXPRESSION 107 F BERNHARD, C KLAMMT.
AND H RUTERJANS. UNIVERSITY OF FRANKFURT I MAIN, GERMANY 3.07 CHEMICAL
BIOLOGY 129 R FLAUMENHAFT, HARVARD MEDICAL SCHOOL, BOSTON, MA, USA VIII
CONTENTS TARGET VALIDATION 3.08 GENETICALLY ENGINEERED ANIMALS 151 B
BOLON, GEMPATH INC., CEDAR CITY, UF. USA 3.09 SMALL INTERFERING
RIBONUCLEIC ACIDS 171 L GIANELLINI AND J MOLL, NERVIANO MEDICAL SCIENCES
S.R.L, NERVIANO, ITALY 3.10 SIGNALING CHAINS 189 M-H TEITEN, R BLASIUS,
F MORCEAU, AND M DIEDERICH, HOPITAL KIRCHBERG, LUXEMBOURG CITY,
LUXEMBOURG, AND M DICATO, CENTRE HOSPITALIER DE LUXEMBOURG, LUXEMBOURG
CITV, LUXEMBOURG 3.11 ORTHOGONAL LIGAND-RECEPTOR PAIRS 215 F C ACHER,
UNIVERSITE RENE DESCARTES PARIS V, PARIS, FRANCE INFORMATICS AND
DATABASES 3.12 CHEMOINFORMATICS 235 V J GILLET, UNIVERSITY OF SHEFFIELD,
SHEFFIELD, T/K AND A R LEACH, GLAXOSMITHKLINE, STEVENAGE, UK 3.13
CHEMICAL INFORMATION SYSTEMS AND DATABASES 265 T ENGEL, CHEMICAL
COMPUTING GROUP AG, KOLN, GERMANY AND E ZASS, INFORMATIONSZENTRUM CHEMIE
BIOLOGIC PHARMAZIE, ZURICH, SWITZERLAND 3.14 BIOACTIVITY DATABASES 293 M
OLAH AND T I OPREA, UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE,
ALBUQUERQUE, NM, USA 3.15 BIOINFORMATICS 315 T LENGAUER AND C HARTMANN,
MAX PLANCK INSTITUTE FOR INFORMATICS, SAARHRUCKEN, GERMANY 3.16 GENE AND
PROTEIN SEQUENCE DATABASES 349 M-J MARTIN, T KULIKOVA, M PRUESS, AND R
APWEILER, EMBL OUTSTATION EUROPEAN BIOINFORMATICS INSTITUTE, HINXTON,
CAMBRIDGE, UK 3.17 THE RESEARCH COLLABORATOR FOR STRUCTURAL
BIOINFORMATICS PROTEIN DATA BANK 373 P E BOURNE, W F BLUHM, N DESHPANDE,
AND Q ZHANG, UNIVERSITY OF CALIFORNIA, LA JOLLA, CA, USA, AND H M BERMAN
AND J L FLIPPEN-ANDERSON, RUTGERS - THE STATE UNIVERSITY OF NEW JERSEY,
PISCATAWAY, NJ, USA 3.18 THE CAMBRIDGE CRYSTALLOGRAPHIC DATABASE 389 F H
ALLEN, G M BATTLE, AND S ROBERTSON, CAMBRIDGE CRYSTALLOGRAPHIC DATA
CENTRE, CAMBRIDGE, UK STRUCTURAL BIOLOGY 3.19 PROTEIN PRODUCTION FOR
THREE-DIMENSIONAL STRUCTURAL ANALYSIS 411 M M T BAUER AND G SCHNAPP,
BOEHRINGER INGELHEIM PHARMA, BIHERACH, GERMANY 3.20 PROTEIN
CRYSTALLIZATION 433 G E SCHULZ, ALBERT-LUDWIGS-U'NIVERSITAT, FREIBURG IM
BREISGAU, GERMANY 3.21 PROTEIN CRYSTALLOGRAPHY 449 M T STUBBS II, MARTIN
LUTHER UNIVERSITY, HALLE, GERMANV CONTENTS IX 3.22 BIO-NUCLEAR MAGNETIC
RESONANCE 473 T CARLOMAGNO, M BALDUS, AND C GRIESINGER. MAX PLANCK
INSTITUTE FOR BIOPHYSICAL CHEMISTRY. GOTTINGEN. GERMANY 3.23 PROTEIN
THREE-DIMENSIONAL STRUCTURE VALIDATION 507 R P JOOSTEN, CENTRE FOR
MOLECULAR AND BIOMOLECULAR INFORMATICS, NIJMEGEN. THE NETHERLANDS, AND G
CHINEA, CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY. HAVANA, CUBA,
AND G J KLEYWEGT. UNIVERSITY OF UPPSALA, UPPSALA. SWEDEN, AND G VRIEND,
CENTRE FOR MOLECULAR AND BIOMOLECULAR INFORMATICS, NIJMEGEN, THE
NETHERLANDS 3.24 PROBLEMS OF PROTEIN THREE-DIMENSIONAL STRUCTURES 531 R
A LASKOWSKI AND G J SWAMINATHAN. EUROPEAN BIOINFORMATICS INSTITUTE.
WELLCOME TRUST GENOME CAMPUS, HINXTON, CAMBRIDGE, UK 3.25 STRUCTURAL
GENOMICS 551 W SHI AND M R CHANCE, CASE WESTERN RESERVE UNIVERSITY.
CLEVELAND. OH. USA SCREENING 3.26 COMPOUND STORAGE AND MANAGEMENT 561 W
W KEIGHLEY. T P WOOD, AND T J WINCHESTER. PFIZER GLOBAL RESEARCH AND
DEVELOPMENT. SANDWICH. UK 3.27 OPTICAL ASSAYS IN DRUG DISCOVERY 577 B
SCHNURR. T AHRENS, AND U REGENASS. DISCOVERY PARTNERS INTERNATIONAL AG,
ALLSCHWIL, SWITZERLAND 3.28 FLUORESCENCE SCREENING ASSAYS 599 D ULLMANN,
EVOTEC AG, HAMBURG. GERMANY 3.29 CELL-BASED SCREENING ASSAYS 617 A
WEISSMAN, J K.EEFER. A MIAGKOV. M SATHYAMOORTHY. S PERSCHKE. AND F L
WANG. NOVASCRCEN BIOSCIENCES CORPORATION. HANOVER. MD. USA 3.30 SMALL
ANIMAL TEST SYSTEMS FOR SCREENING 647 M MUDA, S MCKENNA. AND B G HEALEY.
SERONO RESEARCH INSTITUTE. ROCKHNUL. MA. USA 3.31 IMAGING 659 P M
SMITH-JONES. MEMORIAL SLOAN KCLTERING CANCER CENTER. NEW YORK. NY. USA
3.32 HIGH-THROUGHPUT AND HIGH-CONTENT SCREENING 679 M CIK. JOHNSON &
JOHNSON PHARMACEUTICAL RESEARCH CV DEVELOPMENT. BEERSC. BELGIUM AND M R
JURZAK. MERCK KGAA. DARMSTADT. GERMAIN CHEMICAL TECHNOLOGIES 3.33
COMBINATORIAL CHEMISTRY 69" P SEN LCI. DESENZANO DEL GARDA. ITALY 3.34
SOLUTION PHASE PARALLEL CHEMISTRY 7DL M ASHTON AND B MOLONEY. EVOTEC UK
LTD. AHINGDON. IK 3.35 POLYMER-SUPPORTED REAGENTS AND SCAVENGERS IN
SYNTHESIS 791 S V LEY. I R BAXENDALE. AND R M MYERS. UNIVERSITY OF
CAMBRIDGE. CAMBRIDGE. UK CONTENTS 3.36 MICROWAVE-ASSISTED CHEMISTRY 837
C O KAPPE, KARL-FRANZENS-UNIVERSITY GRAZ, GRAZ, AUSTRIA 3.37
HIGH-THROUGHPUT PURIFICATION 861 D B KASSEL, TAKEDA SAN DIEGO. INC., SAN
DIEGO, CA, USA LEAD SEARCH AND OPTIMIZATION 3.38 PROTEIN CRYSTALLOGRAPHY
IN DRUG DISCOVERY 875 T HOGG AND R HILGENFELD, UNIVERSITY OF LIIBECK,
LIIBECK, GERMANY 3.39 NUCLEAR MAGNETIC RESONANCE IN DRUG DISCOVERY 901 J
KLAGES AND H KESSLER, TU MUNCHEN, GARCHING, GERMANY 3.40 CHEMOGENOMICS
921 H KUBINYI, UNIVERSITY OF HEIDELBERG, HEIDELBERG, GERMANY 3.41
FRAGMENT-BASED APPROACHES 939 W JAHNKE, NOVARTIS PHARMA AG, BASEL,
SWITZERLAND 3.42 DYNAMIC LIGAND ASSEMBLY 959 O RAMSTROM, ROYAL INSTITUTE
OF TECHNOLOGY, STOCKHOLM, SWEDEN AND J-M LEHN, ISIS UNIVERSITE LOUIS
PASTEUR, STRASBOURG, FRANCE SUBJECT INDEX 977 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV022238844 |
| ctrlnum | (OCoLC)634912343 (DE-599)BVBBV022238844 |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01128nam a2200301 cc4500</leader><controlfield tag="001">BV022238844</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070124s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0080445160</subfield><subfield code="9">0-08-044516-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780080445168</subfield><subfield code="9">978-0-08-044516-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)634912343</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022238844</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comprehensive medicinal chemistry II</subfield><subfield code="n">3</subfield><subfield code="p">Drug discovery technologies</subfield><subfield code="c">ed.-in-chief: John B. Taylor...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam [u.a.]</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIX, 1037 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, John B.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="w">(DE-604)BV022238800</subfield><subfield code="g">3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015449802&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015449802</subfield></datafield></record></collection> |
| id | DE-604.BV022238844 |
| illustrated | Illustrated |
| index_date | 2024-07-02T16:35:12Z |
| indexdate | 2024-07-09T20:53:05Z |
| institution | BVB |
| isbn | 0080445160 9780080445168 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015449802 |
| oclc_num | 634912343 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-20 |
| owner_facet | DE-19 DE-BY-UBM DE-20 |
| physical | XXIX, 1037 S. Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Elsevier |
| record_format | marc |
| spelling | Comprehensive medicinal chemistry II 3 Drug discovery technologies ed.-in-chief: John B. Taylor... 1. ed. Amsterdam [u.a.] Elsevier 2007 XXIX, 1037 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Taylor, John B. Sonstige oth (DE-604)BV022238800 3 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015449802&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Comprehensive medicinal chemistry II |
| title | Comprehensive medicinal chemistry II |
| title_auth | Comprehensive medicinal chemistry II |
| title_exact_search | Comprehensive medicinal chemistry II |
| title_exact_search_txtP | Comprehensive medicinal chemistry II |
| title_full | Comprehensive medicinal chemistry II 3 Drug discovery technologies ed.-in-chief: John B. Taylor... |
| title_fullStr | Comprehensive medicinal chemistry II 3 Drug discovery technologies ed.-in-chief: John B. Taylor... |
| title_full_unstemmed | Comprehensive medicinal chemistry II 3 Drug discovery technologies ed.-in-chief: John B. Taylor... |
| title_short | Comprehensive medicinal chemistry II |
| title_sort | comprehensive medicinal chemistry ii drug discovery technologies |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015449802&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV022238800 |
| work_keys_str_mv | AT taylorjohnb comprehensivemedicinalchemistryii3 |